Effect of the APP17 peptide on diabetic encephalopathy

LJ. Liu, XJ. Lu, JM. Gao, RJ. Wang, GX. Cheng

Article ID: 4525
Vol 33, Issue 1, 2019
DOI: https://doi.org/10.54517/jbrha4525
Received: 5 November 2018; Accepted: 5 November 2018; Available online: 11 March 2019; Issue release: 11 March 2019

Abstract

This study aimed to investigate the effect of the APP17 peptide on diabetic encephalopathy. Streptozotocin (STZ)-induced type 2 diabetes mellitus rats were used to obtain a model of diabetic encephalopathy with cognitive impairment. After treatment with APP17 peptide, the changes in blood glucose levels, body weight, and memory ability in the model rats were observed. Glucose metabolism was detected by Positron Emission Tomography/Computerized Tomography (PET/CT) in brain of rats from each group. After 12 weeks of STZ-induced diabetes, the escape latency of the diabetic encephalopathy (DE) group was significantly prolonged compared with the normal control (NC) group (p<0.05) and the uptake of glucose in the cerebral cortex and hippocampus was decreased compared with the NC group. The glucose uptake was significantly increased in the group treated with APP17 (APP17+DE), compared with the DE groups and the level of glucose metabolism in brain tissue was greatly improved (p<0.05). In conclusion, it was confirmed that APP17 peptide could improve the cognitive function and glucose metabolism in diabetic encephalopathy rats.


Keywords

PET/CT imaging technology;diabetes;insulin signaling


References

Supporting Agencies



Copyright (c) 2019 LJ. Liu, XJ. Lu, JM. Gao, RJ. Wang, GX. Cheng




This site is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).